Can-Fite, Cipher deal

Can-Fite granted Cipher rights to commercialize Can-Fite’s CF101 in Canada to treat moderate to severe psoriasis and rheumatoid arthritis. The adenosine A3 receptor (ADORA3) agonist has completed a Phase II/III trial to treat psoriasis and a Phase IIb trial to treat active RA. The partners said that the timing of regulatory submissions in Canada will be determined by the completion of the remaining clinical trial program. ...